品牌	貨號	產品規格	價格(RMB)	庫存（上海）	北京	武漢	南京
源葉(MedMol)	S84205-1mg	99%	￥476.00元	預計交期：2-3天	-	-	-
源葉(MedMol)	S84205-2mg	99%	￥816.00元	5	-	-	-
源葉(MedMol)	S84205-5mg	99%	￥1224.00元	4	-	-	-
源葉(MedMol)	S84205-10mg	99%	￥1972.00元	6	-	-	-
源葉(MedMol)	S84205-25mg	99%	￥3876.00元	6	-	-	-
源葉(MedMol)	S84205-50mg	99%	￥6600.00元	5	-	-	-
源葉(MedMol)	S84205-100mg	99%	￥8900.00元	預計交期：2-3天	-	-	-

產品介紹

Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

產品描述： Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

靶點： ERK1:5 nM (IC50);ERK2:5 nM (IC50);ERK

體外研究：
Temuterkib is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. In an unbiased tumor cell panel sensitivity profiling for inhibition of cell proliferation, tumor cells with MAPK pathway alterations including BRAF, NRAS or KRAS mutation are generally sensitivity to Temuterkib

體內研究：
In tumor xenograft models, Temuterkib inhibits PD biomarker phospho-p90RSK1 in tumors and the PD effects are correlated with compound exposures and anti-tumor activities. Temuterkib shows either similar or superior anti-tumor activity as compared to other published ERK inhibitors in BRAF or RAS mutant cell lines and xenograft models. Oral administration of single-agent Temuterkib significantly inhibits tumor growth in vivo and is well tolerated in BRAF or NRAS mutant melanoma, BRAF or KRAS mutant colorectal, lung and pancreatic cancer xenografts or PDX models. Therefore, Temuterkib can be tailored for treatment of cancers with MAPK pathway alteration. In addition, Temuterkib has anti-tumor activity in a PLX4032-resistant A375 melanoma xenograft model due to MAPK reactivation, may have potential for treatment of melanoma patients who have failed BRAF therapies. More importantly, Temuterkib can be combined with investigational and approved agents in preclinical models, particularly KRAS mutant models. Combination treatment of Temuterkib and CDK4/6 inhibitor abemaciclib is well tolerated and results in potent tumor growth inhibition or regression in multiple in vivo cancer models, including KRAS mutant colorectal and non-small cell lung cancers

參考文獻：
1. Shripad V. Bhagwat, et al. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Cancer Research. July 2017.

溶解性： Soluble in DMSO

保存條件： -20℃

配置溶液濃度參考：

	1mg	5mg	10mg
1 mM	2.205 ml	11.024 ml	22.048 ml
5 mM	0.441 ml	2.205 ml	4.41 ml
10 mM	0.22 ml	1.102 ml	2.205 ml
50 mM	0.044 ml	0.22 ml	0.441 ml

注意：

部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。

參考文獻(1篇)

1. [IF=4.9] Xin Li et al."Paeonol Relieves Chronic Neuropathic Pain by Reducing Communication Between Schwann Cells and Macrophages in the Dorsal Root Ganglia After Injury."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2025 Jan;26(9):3964

質檢證書(COA)

輸入產品批號：

如何獲取質檢證書(COA)?

請輸入貨號和一個與之匹配的批號。
例如:
批號：C10000001 貨號：A800001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

質量

濃度

體積

分子摩爾量

計算重置

玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

產品中心

Product center

LY3214996 99%

LY3214996